# Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

> **NCT01639911** · PHASE1 · COMPLETED · sponsor: **University of Illinois at Chicago** · enrollment: 28 (actual)

## Conditions studied

- Malignant Neoplasm of Breast
- CNS Malignancy
- Malignant Neoplasm of Gastrointestinal Tract
- Genitourinary Neoplasms Malignancy and Gender Unspecified
- Head and Neck Neoplasms
- Melanoma
- Malignant Neoplasm of Thorax

## Interventions

- **DRUG:** Alisertib
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01639911
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-14
- **Primary completion:** 2016-07-28
- **Final completion:** 2016-07-28
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01639911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01639911, "Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01639911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*